Company newsroom

ADC Therapeutics SA

NYSE:ADCT

3 releases

ADC Therapeutics SANov 4, 2026

ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR…

ADC Therapeutics SANov 3, 2026

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…

ADC Therapeutics SANov 2, 2026

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that…